The pathophysiology and treatment of rhinitis medicamentosa.
To evaluate the treatment of rhinitis medicamentosa, 10 consecutive patients discontinued their use of topical vasoconstrictors and were treated with budesonide nasal spray, 400 micrograms, daily for 6 weeks. The thickness of the nasal mucosa, the decongestive effect of oxymetazoline and the histamine sensitivity were measured with rhinostereometry. All patients were able to stop using the vasoconstrictors and objective variables showed that they needed treatment for at least 6 weeks. The results strongly support the theory that the rebound swelling is due to interstitial oedema rather than to vasodilatation. The presence of tachyphylaxis reflected by a reduction in both the decongestive effect of oxymetazoline and a reduction of drug duration was seen.
Graf
P
P
Department of Otorhinolaryngology, Södersjukhuset, Karolinska Institute, Stockholm, Sweden.
Hallén
H
H
Juto
J E
JE
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D019819:Budesonide; D005260:Female; D005938:Glucocorticoids; D006632:Histamine / Q000378:metabolism; D006801:Humans; D008297:Male; D009297:Nasal Mucosa / Q000187:drug effects; D011282:Pregnenediones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D012223:Rhinitis, Vasomotor / Q000188:drug therapy* / Q000503:physiopathology*; D013618:Tachyphylaxis
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011282:Pregnenediones; D019819:Budesonide; D006632:Histamine